<DOC>
	<DOCNO>NCT02992223</DOCNO>
	<brief_summary>Evaluate Y90 Ibritumomab Tiuxetan Radioimmunotherapy addition standard high dose chemotherapy follow autologous stem cell transplant could improve prognosis patient affect relapsed/refractory aggressive non Hodgkin lymphoma</brief_summary>
	<brief_title>Retrospective Analysis Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCT</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>High Risk Relapsed/refractory aggressive nonhodgkin lymphoma define : Progressive disease Early relapse ( within 12 month response ) Recurrent relapse Treated salvage chemotherapy follow Y90 Ibritumomab Tiuxetan plus highdose chemotherapy Autologous stem cell transplant Age &gt; 18 year Previous treatment Rituximab Written inform consent Patient complete data available collection</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Aggressive B-cell non-Hodgkin Lymphoma</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Zevalin</keyword>
	<keyword>Y90 Ibritumomab Tiuxetan</keyword>
	<keyword>Autologous stem cell transplant</keyword>
	<keyword>BEAM</keyword>
	<keyword>Recurrent</keyword>
</DOC>